Home Monitoring in Washington

Cadwell Industries is a family-owned American manufacturer specializing in neurodiagnostic, neuromonitoring, and sleep diagnostic medical devices. Founded in 1979 and headquartered in Kennewick, Washington, the company employs approximately 260–281 people and maintains a strong commitment to in-house research and development. Cadwell's product portfolio includes the Sierra EMG/NCS/EP/Ultrasound systems for electromyography, nerve conduction studies, and evoked potentials; Arc EEG systems for electroencephalography and epilepsy monitoring; Cascade IONM equipment for intraoperative neurophysiological monitoring; and ApneaTrak HSAT and PSG systems for sleep diagnostics. The company also manufactures a comprehensive range of electrodes, consumables, supplies, and accessories for neurology applications. Cadwell serves hospitals, clinics, and home-care settings with global distribution, supported by dedicated customer service, online training resources, and educational workshops.

Modus Health manufactures StepWatch®, an FDA-listed and CE-marked wearable activity monitoring device validated in over 600 peer-reviewed publications across 40+ patient conditions. The StepWatch® is the gold standard for accurate step counting and activity measurement, used by researchers at major technology companies (Google, Fitbit, Samsung Digital Health) to validate their fitness monitors. The company serves three primary market segments: clinical trials, research institutions, and ongoing clinical care. With presence in 145 clinical sites across 71 countries, Modus Health specializes in precision activity monitoring for outcomes measurement and clinical decision-making. The platform includes custom software solutions tailored to clinical trials, research, and clinical care workflows. Products are supported by robust clinical evidence demonstrating superior accuracy in measuring walking activity compared to consumer-grade monitors. The company provides customer support Monday–Friday, 9:00 AM–5:00 PM PST, with 24-hour response target for support requests.

Continua Systems is a device operations platform and logistics partner for digital health and remote patient monitoring (RPM) companies. The company specializes in 4G cellular-based connected health devices, providing end-to-end device operations including sourcing, connectivity management, fulfillment, and returns. Continua handles device logistics and operations so that software companies and RPM platforms can focus on clinical application and patient engagement. The platform features automatic network selection across major US carriers (AT&T, T-Mobile, Verizon) for reliable coverage, a robust API for seamless integration, secure certificate-based infrastructure, 24/7 customer support, and flexible shipping from national warehouse networks. Target customers are digital health and RPM companies ordering hundreds to thousands of devices monthly. Continua positions itself as a trusted operational partner enabling clients to scale efficiently, improve patient retention, reduce costs, and enhance data security and quality.

Fairhaven Health is a specialty supplier of clinically-designed nutritional supplements and wellness products supporting women's health across all life stages. The company manufactures ISO-13485 certified products in GMP-certified North American facilities, focusing on fertility enhancement, pregnancy support, breastfeeding nutrition, and women's general wellness. Product lines include FertilAid and FH PRO fertility multivitamins for men and women, prenatal supplements with nausea-relief formulations, postnatal and lactation support products, menopause relief supplements, myo-inositol for PCOS support, fertility lubricants (BabyDance), and early pregnancy detection tests. All formulations are hormone-free and paraben-free. Founded in 2003 and based in Bellingham, Washington, Fairhaven Health serves healthcare practitioners and direct-to-consumer channels with evidence-based nutritional solutions.

Remmie Health manufactures FDA-registered, portable digital otoscopes designed for home and telehealth-enabled ear, nose, and throat (ENT) examination and remote sharing with healthcare providers. The company's core product line includes the Remmie 3 and Remmie 4, intelligent otoscope cameras with high-definition (720p) imaging, wireless connectivity, real-time video streaming capabilities, and cloud-enabled mobile applications for iOS and Android devices. Remmie devices feature 3.9mm diameter lenses, adjustable brightness (5 levels), waterproof design, 2.4GHz Wi-Fi connectivity, and battery life supporting extended use. All devices ship with disposable specula, cleaning pads, charging accessories, and setup guidance. The Remmie App provides AI-guided image capture, local recording and saving of images and video, and live streaming to clinicians for remote diagnosis and intervention without requiring an internet connection for basic operation. The company targets parents, caregivers, and patients managing common ear and upper respiratory conditions (otitis media, otitis externa, sinusitis, pharyngitis, tonsillitis, strep throat, pink eye) while reducing costly emergency room and urgent care visits. Remmie devices are FDA Class 1 registered, CE marked, and cleared by Health Canada and Australian TGA. The company explicitly clarifies that Remmie devices are examination tools only and does not provide diagnostic, prescription, or telehealth services; users must consult independent healthcare providers for clinical care. Regulatory compliance and clinical validation are central to the company's positioning.

Kestra Medical Technologies manufactures the ASSURE® Wearable Cardioverter Defibrillator (WCD) system, a non-invasive, wearable medical device designed to protect patients at elevated risk of sudden cardiac arrest (SCA). The system targets heart failure patients and those with reduced left ventricular ejection fraction (LVEF ≤35%) awaiting clinical improvement or subsequent therapeutic intervention. The ASSURE system comprises three integrated components: the wearable defibrillator device with autonomous arrhythmia detection and highly effective defibrillation therapy; the Kestra CareStation™, a cloud-based remote patient data management platform enabling clinician oversight and patient data integration; and the ASSURE patient mobile application to enhance compliance and patient engagement during recovery. The company positions itself at the intersection of digital health, smart wearables, mobile connectivity, and cardiac protection. Kestra's clinical evidence includes the ACE-PAS (ASSURE® WCD Clinical Evaluation Post-Approval Study), described as the largest prospective real-world study of wearable defibrillators to date, demonstrating safety, performance, and real-world effectiveness. The device is FDA-cleared and represents a modern approach to temporary cardiac risk management in ambulatory and home settings. Kestra serves cardiologists, hospitals, and heart failure programs across the United States and maintains international presence.

SeniorLife.AI is an AI-powered wellness platform designed for senior living operators, longevity clinics, concierge medicine practices, and rehabilitation providers. The platform utilizes vision-based artificial intelligence and passive monitoring technologies to predict mobility and cognitive decline risk months to years in advance. Core capabilities include Risk Insights (AI-trained on 4M mobility records and 2.5M cognitive decline cases), Mobility Metrics Tracker (FDA Class II SaMD—30 gait and balance metrics from 30-second smartphone video), Gaze Metrics Analysis (5-minute iPad eye movement test for early cognitive impairment detection), and Dynamic Care Plan (role-specific action synthesis integrated with EHR systems via SMART on FHIR). The platform also features passive 24/7 room radar monitoring and on-demand vitals scanning. Trained on Mayo Clinic records, SeniorLife.AI integrates seamlessly into existing clinical workflows and can be white-labeled via API. The solution targets fall prevention, functional performance tracking, and objective evidence for discharge planning and CMS reimbursement justification in post-acute care settings.

Prestige Medical is a B2B medical device manufacturer specializing in diagnostic instruments and clinical tools for healthcare professionals. The company offers a comprehensive range of stethoscopes (including Littmann® brand), aneroid sphygmomanometers, blood pressure monitors, digital thermometers, pulse oximeters, otoscopes, penlights, neurological hammers, and surgical instruments such as forceps and scissors. Beyond clinical diagnostics, Prestige Medical supplies medical apparel and professional accessories including lab coats, scrubs, compression sleeves, and branded healthcare worker apparel. The product portfolio encompasses combination diagnostic kits, dissection kits, measuring tools, and replacement parts. The company operates a B2B retail partner model with a "Find a Retailer" locator and supports healthcare institutions, clinics, and individual practitioners through both direct and distributed channels.

Tasso Inc. is a Seattle-based healthcare technology company founded in 2014 that specializes in transforming at-home blood collection through innovative, patient-centric devices. The company offers an end-to-end platform for decentralized clinical trials and remote blood sample collection, eliminating the need for traditional phlebotomy and venipuncture. Tasso's proprietary devices—Tasso+ and Tasso Mini—enable virtually painless capillary blood sampling, improving patient experience and engagement while reducing collection anxiety. The Tasso+ device collects whole liquid blood compatible with standard collection tubes, while Tasso Mini is optimized for longitudinal sampling, frequent testing, and sensitive populations including pediatrics. Beyond hardware, Tasso provides comprehensive logistics support including sample shipping, live proctoring, SMS reminders, and lab integration. The platform supports diverse clinical applications including population pharmacokinetic (PopPK) studies, clinical trial prescreening, pediatric research, and anti-doping testing. Tasso has established partnerships with major laboratories and healthcare organizations such as ARUP Laboratories and InnoVero, and is cited in over 100 peer-reviewed publications. The solution addresses critical barriers to diagnostic access, particularly in decentralized and remote care settings.